The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Mavyret (glecaprevir and pibrentasvir)

Are there any other warnings one should know regarding Mavyret?

Risk of Hepatitis B Reactivation

The FDA has indicated that there is risk of the Hepatitis B virus becoming an active infection again in any patient who has a current or previous infection with Hepatitis B virus and is being treated with Mavyret, a direct-acting antiviral medicine for Hepatitis C virus. In a few cases, Hepatitis B virus reactivation in patients treated with these types of medicines resulted in serious liver problems or death. In addition to a prominent warning being required on the medication’s labeling, healthcare professionals are being directed to also screen and monitor for the Hepatitis B virus in all patients receiving this treatment.

Last Updated: October 2017

"FDA approves Mavyret for Hepatitis C." U.S. Food & Drug Administration. Retrieved October 6, 2017.

"Highlights of Prescribing Information." AbbVie Inc., Retrieved October 6, 2017.

"Mavyret Product Summary." AbbVie Inc., Retrieved October 6, 2017.

"Introducing MavyRet." AbbVie Inc., Retrieved October 6, 2017.